ERBB2 and colorectal cancer: Since clinical and experimental evidences show a role for over-expression of the HER2 protein in the progression of human breast, ovarian, non-small cell lung [6] and colorectal cancer [7], HER2 may be a candidate target for receptor-targeted therapeutics.